Background: In recent years, there has been an ongoing interest in topical treatment for lentigo maligna (LM) as imiquimod 5% cream owing to the localization of this tumor and the advanced age of patients; however, the efficacy of imiquimod 5% cream is controversial, and the rate of local relapses is about 25-53%. Reflectance confocal microscopy (RCM) is a noninvasive diagnostic tool useful not only for diagnostic purpose but also for monitoring the response to the local treatment of LM. Our aim was to demonstrate the role of RCM in the follow-up of a topical treatment with imiquimod 5% cream in clinical practice.
Methods: We report three patients with histopathologically confirmed LM who were not candidates for surgery and were successfully treated with imiquimod 5% cream. In such patients, dermatoscopic images and reflectance confocal microscopy were useful to evaluate treatment response and to verify long-term clinical benefits during the follow-up visits.
Results: No relapses were observed in our patients 18 months after the end of treatment; although, continuous follow-up visits are needed in these patients.
Conclusions: In the case series presented herein, we highlight the importance of RCM as a noninvasive tool to monitor the efficacy of imiquimod to treat LM during and after treatment. Detailed confocal images of two of our patients allowed us to establish the persistence of atypical cells and to continue treatment, although clinical and dermatoscopic examinations showed "apparent complete remission" after the first cycle of therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.15070 | DOI Listing |
Acta Pharmacol Sin
January 2025
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Psoriasis is a chronic, systemic immune-mediated skin disease. Although many new strategies for psoriasis treatment have been developed, there is great need in clinic for treating psoriasis. Gentiopicroside (GPS), derived from Gentiana manshurica Kitagawa, has multiple pharmacological activities including anti-inflammatory, anti-oxidative and antiviral activities.
View Article and Find Full Text PDFJ Prosthodont Res
January 2025
Division of Bio-prosthodontics, Department of Oral Health Science, Niigata University Graduate School of Medical and Dental Sciences, Gakkocho-dori, Chuo-ku, Niigata Japan.
Purpose: Psoriasis is a complex, chronic inflammatory keratosis of unclear origin that is challenging to treat. In patients with psoriasis suspected of having metal allergies, the removal of oral metallic prostheses contributes to the alleviation of psoriasis symptoms. However, the relationship and mechanism of the metal removal effect and improvement in psoriasis symptoms in patients with metal allergies are unknown.
View Article and Find Full Text PDFOral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil. Electronic address:
Objective: actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.
View Article and Find Full Text PDFDermatol Reports
November 2024
Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.
View Article and Find Full Text PDFEur Urol Open Sci
January 2025
Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Introduction And Objective: Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!